Page 137 - Binder2
P. 137
From Molecule-Centric to Immune-Centric
Design
In the platform model, the immune system isn’t treated as
an obstacle—it’s treated as a design partner.
Every step of development—from antigen selection to
delivery method—is informed by how the therapy will be
received immunologically. That means:
• Engaging tolerance pathways early through oral or
mucosal delivery
• Reducing immunogenic flags through low-noise
expression platforms
• Including tolerogenic adjuvants to instruct
acceptance from first exposure
• Layering in ADA tracking, Treg recruitment
data, and immune biomarkers throughout
development
This is not just a better way to build one drug.
It’s a replicable architecture—a foundation that can be
reused across indications, mechanisms, and modalities.
Durability Becomes the Differentiator
In a patchwork model, differentiation often comes down to:
• Slight improvements in efficacy curves
• Modified dosing schedules
• Marketing around patient convenience or biomarker
targeting
135
